These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 18596992)

  • 1. Molecule of the month. Odanacatib.
    Drug News Perspect; 2008 Jun; 21(5):281. PubMed ID: 18596992
    [No Abstract]   [Full Text] [Related]  

  • 2. Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling.
    Lewiecki EM
    IDrugs; 2009 Dec; 12(12):799-809. PubMed ID: 19943223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Odanacatib: an emerging novel treatment alternative for postmenopausal osteoporosis.
    Schultz TC; Valenzano JP; Verzella JL; Umland EM
    Womens Health (Lond); 2015 Nov; 11(6):805-14. PubMed ID: 26344800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies.
    Stoch SA; Zajic S; Stone J; Miller DL; Van Dyck K; Gutierrez MJ; De Decker M; Liu L; Liu Q; Scott BB; Panebianco D; Jin B; Duong LT; Gottesdiener K; Wagner JA
    Clin Pharmacol Ther; 2009 Aug; 86(2):175-82. PubMed ID: 19421185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cathepsin K antagonists: preclinical and clinical data].
    Gamsjäger M; Resch H
    Wien Med Wochenschr; 2015 Feb; 165(3-4):65-70. PubMed ID: 25572547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
    Gauthier JY; Chauret N; Cromlish W; Desmarais S; Duong LT; Falgueyret JP; Kimmel DB; Lamontagne S; Léger S; LeRiche T; Li CS; Massé F; McKay DJ; Nicoll-Griffith DA; Oballa RM; Palmer JT; Percival MD; Riendeau D; Robichaud J; Rodan GA; Rodan SB; Seto C; Thérien M; Truong VL; Venuti MC; Wesolowski G; Young RN; Zamboni R; Black WC
    Bioorg Med Chem Lett; 2008 Feb; 18(3):923-8. PubMed ID: 18226527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Odanacatib for the treatment of osteoporosis.
    Boggild MK; Gajic-Veljanoski O; McDonald-Blumer H; Ridout R; Tile L; Josse R; Cheung AM
    Expert Opin Pharmacother; 2015; 16(11):1717-26. PubMed ID: 26149759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of postmenopausal osteoporosis with odanacatib.
    Chapurlat RD
    Expert Opin Pharmacother; 2014 Mar; 15(4):559-64. PubMed ID: 24456412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cathepsin K inhibitor: new therapy approach against osteoporosis. Pharmacological target in the osteoclast].
    Aumiller J
    MMW Fortschr Med; 2011 May; 153(19):16. PubMed ID: 21612088
    [No Abstract]   [Full Text] [Related]  

  • 10. Discontinuation of odanacatib and other osteoporosis treatments: here today and gone tomorrow?
    Bauer DC
    J Bone Miner Res; 2011 Feb; 26(2):239-41. PubMed ID: 21254231
    [No Abstract]   [Full Text] [Related]  

  • 11. A practical enantioselective synthesis of odanacatib, a potent Cathepsin K inhibitor, via triflate displacement of an alpha-trifluoromethylbenzyl triflate.
    O'Shea PD; Chen CY; Gauvreau D; Gosselin F; Hughes G; Nadeau C; Volante RP
    J Org Chem; 2009 Feb; 74(4):1605-10. PubMed ID: 19140725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetic Analysis of the Cathepsin K Inhibitor Odanacatib: Insights Into Intrinsic and Extrinsic Factor Effects on Exposure in Postmenopausal and Elderly Women.
    Jaworowicz D; Bihorel S; Zajic S; Stoch SA; Humphrey R; McCrea JB; Stone JA
    J Clin Pharmacol; 2020 Aug; 60(8):1107-1123. PubMed ID: 32302427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptidomimetic inhibitors of cathepsin K.
    Black WC
    Curr Top Med Chem; 2010; 10(7):745-51. PubMed ID: 20337585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cathepsin K inhibitors: emerging treatment options for osteoporosis.
    Pietschmann P
    Wien Med Wochenschr; 2015 Feb; 165(3-4):47. PubMed ID: 25690879
    [No Abstract]   [Full Text] [Related]  

  • 15. Difluoroethylamines as an amide isostere in inhibitors of cathepsin K.
    Isabel E; Mellon C; Boyd MJ; Chauret N; Deschênes D; Desmarais S; Falgueyret JP; Gauthier JY; Khougaz K; Lau CK; Léger S; Levorse DA; Li CS; Massé F; Percival MD; Roy B; Scheigetz J; Thérien M; Truong VL; Wesolowski G; Young RN; Zamboni R; Black WC
    Bioorg Med Chem Lett; 2011 Feb; 21(3):920-3. PubMed ID: 21232956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological inhibitors to identify roles of cathepsin K in cell-based studies: a comparison of available tools.
    Desmarais S; Massé F; Percival MD
    Biol Chem; 2009 Sep; 390(9):941-8. PubMed ID: 19453281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential first-in-class osteoporosis drug speeds through trials.
    Williams SC
    Nat Med; 2012 Aug; 18(8):1158. PubMed ID: 22869169
    [No Abstract]   [Full Text] [Related]  

  • 18. Merck &Co. drops osteoporosis drug odanacatib.
    Mullard A
    Nat Rev Drug Discov; 2016 Sep; 15(10):669. PubMed ID: 27681784
    [No Abstract]   [Full Text] [Related]  

  • 19. Morphea-like skin lesions reported in the phase 3 Long-Term Odanacatib Fracture Trial (LOFT) in postmenopausal women with osteoporosis.
    Saag KG; de Villiers TJ; Alexandersen P; Jacobe H; Kovarik C; Werth VP; Leung A; Desai-Merchant A; Mattaliano J; Gurner D
    J Am Acad Dermatol; 2021 Apr; 84(4):1113-1119. PubMed ID: 32553680
    [No Abstract]   [Full Text] [Related]  

  • 20. Osteoporosis & Menopausal Disorders-SMi Conference.
    Foley P
    IDrugs; 2003 Jul; 6(7):660-3. PubMed ID: 12908451
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.